$1.530
-0.020 (-1.29%)Zum Schluss
- Hoch
- 1.587
- Eröffnung
- 1.540
- Volumengewichteter Durchschnittskurs
- 1.54
- Volumen
- 24.82K
- Marktkap.
- —
- Tief
- 1.500
- Umsatz
- 38.20K
- EV/EBITDA, TTM
- 0.00
SL Science Holding Ltd is a Taiwan-based company mainly engaged in the research and development (R&D) of cell and gene therapies for cancer treatment and regenerative medicine. The Company develops investigational immune cell technologies, including gamma delta (γδ) T cells, Armed-T cells and exosome-based formulations, and operates through its biotechnology and oncology research activities.
KI-Analyse of SL Science Holding Ltd (SLBT)
HaltenSL Science Holding Ltd (SLBT) is not a good buy right now due to its current price of $1.53, which is significantly down 73.62% year-to-date. The RSI is at 37.199, indicating that the stock is currently oversold, but the forward P/E ratio is 0, suggesting a lack of earnings expectations. The recent positive news about glioblastoma treatment shows potential, but the company reported a net income loss of $29,122 in Q1 2026, highlighting ongoing financial struggles. The main risk is the extremely high debt to equity ratio of 882.89%, which poses a significant financial risk for investors.
Bewertungskennzahlen
News
9.009-27NASDAQ.COMSL Science Holding Reports Positive Data for Glioblastoma Treatment
9.008-27NASDAQ.COMSL Science Holding Files New Drug Master File with FDA
9.008-27NewsfilterSL Science Files New Drug Master File with FDA
9.508-04NASDAQ.COMBiotech Stocks Surge with Significant Gains
- 8.507-17Newsfilter
SL Science Showcases γδ T Cell Therapy for Glioblastoma
SLBT FAQ – beantwortet von Alphio AI
SL Science Holding Ltd is a Taiwan-based company mainly engaged in the research and development (R&D) of cell and gene therapies for cancer treatment and regenerative medicine. The Company develops investigational immune cell technologies, including gamma delta (γδ) T cells, Armed-T cells and exosome-based formulations, and operates through its biotechnology and oncology research activities. It operates in the Healthcare sector.
SL Science Holding Ltd (SLBT) is not a good buy right now due to its current price of $1.53, which is significantly down 73.62% year-to-date. The RSI is at 37.199, indicating that the stock is currently oversold, but the forward P/E ratio is 0, suggesting a lack of earnings expectations. The recent positive news about glioblastoma treatment shows potential, but the company reported a net income loss of $29,122 in Q1 2026, highlighting ongoing financial struggles. The main risk is the extremely high debt to equity ratio of 882.89%, which poses a significant financial risk for investors.
Community
Mehr ↗Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenDiese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.